Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Browse by collection
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Browse by collection
Archive
Authors
About
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
topic
Journal for ImmunoTherapy of Cancer
Special collections
COVID-19
Email alerts
COVID-19
SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity
Jia
Wei
,
Jianping
Zhao
,
Meifang
Han
,
Fankai
Meng
,
Jianfeng
Zhou
Journal for ImmunoTherapy of Cancer
Jul 2020,
8
(2)
e000862;
DOI:
10.1136/jitc-2020-000862
Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment
Ernesto
Rossi
,
Giovanni
Schinzari
,
Giampaolo
Tortora
Journal for ImmunoTherapy of Cancer
Jul 2020,
8
(2)
e000952;
DOI:
10.1136/jitc-2020-000952
ACE2
and
TMPRSS2
expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19
Riyue
Bao
,
Kyle
Hernandez
,
Lei
Huang
,
Jason John
Luke
Journal for ImmunoTherapy of Cancer
Jul 2020,
8
(2)
e001020;
DOI:
10.1136/jitc-2020-001020
BCG vaccine and COVID-19: implications for infection prophylaxis and cancer immunotherapy
Madhuri
Koti
,
Alvaro
Morales
,
Charles H
Graham
,
David Robert
Siemens
Journal for ImmunoTherapy of Cancer
Jul 2020,
8
(2)
e001119;
DOI:
10.1136/jitc-2020-001119
On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19
Thilo
Gambichler
,
Judith
Reuther
,
Christina H
Scheel
,
Jürgen Christian
Becker
Journal for ImmunoTherapy of Cancer
Jul 2020,
8
(2)
e001145;
DOI:
10.1136/jitc-2020-001145
Pages
« first
‹ previous
1
2
3
4
5
Special collections
COVID-19
(45)
Editor's choice
JITC
Aging and diversity, equity, and inclusion (DEI) with regard to cancer immunotherapy and understudied populations
Aging and diversity, equity, and inclusion (DEI) with regard to cancer immunotherapy and understudied populations
Basic Tumor Immunology
(561)
Case Reports
(191)
Clinical Trials Monitor
(17)
Clinical/Translational Cancer Immunotherapy
(986)
Commentary/Editorials
(154)
Computational I-O
(4)
COVID-19 and Cancer Immunotherapy
(10)
Emerging Immunotherapeutic Agents
(5)
Guidelines and Consensus Statements
(56)
Guidelines and Consensus Statements
(53)
Imaging and Immunotherapy
(9)
Immune Cell Therapies and Immune Cell Engineering
(244)
Immune Checkpoints - Beyond PD-1
(8)
Immune Checkpoints Beyond PD-1 Series
(8)
Immune Monitoring Technology Primers
(12)
Immunotherapy Biomarkers
(440)
Liquid Biopsies
(10)
Microbial-Based Cancer Immunotherapy
(4)
Oncolytic and Local Immunotherapy
(151)
Reviews
(245)
The Next Wave of Immuno-oncology: A Roadmap from the Society for Immunotherapy of Cancer (SITC)
(1)
Open access
(5036)
Press releases
(2)
